This past Tuesday, the Corporis Medical team attended TEFAF Maastricht, courtesy of Brightlands. Our device The Mediclose System was also on display during the Brightlands Symposium that day. Thanks Brightlands for this opportunity!

Corporis Medical completed an all equity financing round, including the conversion of existing convertible loans. The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors, including Brightlands Ventures Partners and LIOF.

Proceeds will be used to fund a Randomized Controlled Trial for Mediclose™, as well as clinical validation of the fully integrated Laprixa™ System. “We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions. This round of funding will allow us to take important steps necessary to enable a market launch” said John Marugg, Chief Executive Officer of Corporis Medical.

EIT Health awards Corporis Medical's “Objective surgical wound healing indicator” with the Quality Label. Following the Business Plan 2022 Call Evaluation by an international panel of independent experts, the proposal was scored as a high-quality project proposal in a highly competitive evaluation process. This project is recommended by EIT Health for additional funding sources.

Corporis Medical has obtained the EN ISO 13485:2016 certification after the successful audit in June 2020 for the design, development, manufacturing and distribution of devices for minimally invasive procedures.

​Together with AIM and Medanco, Corporis Medical is joining forces to develop the smallest blood pressure meter for the diagnostic determination of the blood flow in tissue.

​On March 28 and 29, Brightlands will be exhibiting together with LIOF and the Limburg Employers Association at Limburg Unlimited, the ultimate platform for showcasing the province’s many strengths.

After extensive review of Corporis Medical’s 510(k) pre-market submission, the FDA has granted its approval for the Mediclose™ System to enter the US market!

We are currently entertaining discussion with potential US distributors.

The Corporis Medical Team visited Medica and CompaMed last Tuesday, November 14, 2023. It was an interesting day filled with fruitful discussions and inspiring presentations. 

On June 7th, Corporis Medical passed the annual surveillance audit attesting to our high-quality management system in line with the ISO13485:2016 standard.

Together with AIM and Medace, forces are joined to accelerate the production of the smallest blood pressure monitor, the laprixa.

​Corporis Medical is organizing an in-house ISO 13485:2016 Internal Auditor Training at Brightlands Maastricht Health Campus on 8th and 9th of November 2018.

​In the Series A round, which was led by Chemelot Ventures and assisted by co-investors Limburg Business Development Fund (LBDF) and existing shareholder Inkef Capital, Corporis Medical has raised €2 million which the company intends to use the funding to obtain regulatory approval for the two devices.

Led by our CSO and founder Alexander Veenhof, Corporis Medical’s Mediclose™ System has been validated in patients in a multicenter First-in-Human clinical investigation. With this, we have demonstrated that the Mediclose™ System is safe for use and reduces port closure time significantly, compared to manual closure.

We are happy to announce that Corporis Medical is re-certified according to the ISO 13485:2016 standard. The annual surveillance audit by our notified body DEKRA, was passed with zero findings and no non-conformities.

Klara Scupakova of Corporis Medical gave a Pitch about Corporis Medical and its products at the Brightlands Webinar on the opportunities in the health sector in the Netherlands and Catalonia.

The development of a new generation automatic trocar closure device, including clean room injection molding and scale-up, will be done together with Medanco Rubber & Plastic Solutions B.V. and is made possible by the European fund for regional development MIT ZUID. 

​An Eurostars grant was awarded for the consortium built between Corporis Medical, AIM BV and CSEM SA. The aim of this collaboration is to further develop the Perfusion Measurement technology towards a commercial device.

As of 1 December, Corporis medical will be based at the brightlands health campus at oxfordlaan 55, Maastricht.